for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

36.34USD

Change

-0.16(-0.44%)

Volume

4,388,684

Today's Range

36.32

 - 

36.75

52 Week Range

33.97

 - 

46.46

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
36.50
Open
36.57
Volume
4,388,684
3M AVG Volume
513.98
Today's High
36.75
Today's Low
36.32
52 Week High
46.46
52 Week Low
33.97
Shares Out (MIL)
5,531.05
Market Cap (MIL)
201,883.30
Forward P/E
12.97
Dividend (Yield %)
3.95

Next Event

Q3 2019 Pfizer Inc Earnings Release

Latest Developments

More

Pfizer Presents Positive Phase 3 Data For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer Intends To Submit Results Of Beacon CRC Trial For Marketing Approval In U.S. In Q4 Of 2019

Ian Read To Retire As Executive Chairman Of Pfizer’S Board Of Directors, Chief Executive Officer Albert Bourla Named Chairman

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Ian C. Read

Executive Chairman of the Board

Albert Bourla

Chief Executive Officer, Director

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations

Mikael G. Dolsten

President - Worldwide Research and Development

Michael Goettler

Group President - Pfizer Upjohn

Key Stats

2.50 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

52.8K

2017

52.5K

2018

53.6K

2019(E)

51.4K
EPS (USD)

2016

2.400

2017

2.650

2018

3.000

2019(E)

2.815
Price To Earnings (TTM)
17.85
Price To Sales (TTM)
3.76
Price To Book (MRQ)
3.39
Price To Cash Flow (TTM)
11.09
Total Debt To Equity (MRQ)
78.36
LT Debt To Equity (MRQ)
60.72
Return on Investment (TTM)
9.27
Return on Equity (TTM)
7.40

Latest News

Latest News

Novartis says Kisqali boosts survival in breast cancer patients

Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizer's blockbuster Ibrance.

Pfizer veteran Ian Read to retire as executive chairman

Pfizer Inc <PFE.N> said on Friday Ian Read will retire as executive chairman at the end of this year, after a four-decade association with the largest U.S. drugmaker that included eight years as chief executive officer.

Ian Read to retire as Pfizer executive chairman

Pfizer Inc said on Friday Ian Read will retire as executive chairman at the end of this year, ending a four-decade association with the largest U.S. drugmaker.

Ted Baker taps Debenhams executive Osborne as new CFO

British fashion retailer Ted Baker Plc <TED.L> said on Thursday Rachel Osborne will become its new finance chief once she steps down from the same position at Debenhams, following just one year in the role at the department store chain.

Novartis wins FDA's breakthrough tag for lung cancer hopeful

Novartis <NOVN.S> has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

UPDATE 2-J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc <PFE.N> has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV <MYL.O>, a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2025 GMT on Monday:

Pfizer in talks to transition EpiPen manufacturing into generics spinoff

Pfizer Inc is in talks to merge its contract manufacturer that produces Mylan's EpiPen emergency allergy treatment into the new generics business it has created by combining its older off-patent medicines unit with generic drugmaker Mylan NV, a Pfizer spokeswoman said.

Pfizer posts 30% rise in quarterly profit

Pfizer Inc <PFE.N> on Monday reported a 30% rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.

Mylan to combine with Pfizer's off-patent medicines unit

Mylan NV said on Monday it would combine with Pfizer Inc's off-patent branded and generic established medicines business to form a global generic drugmaker.

Pfizer in talks to merge off-patent drugs business with Mylan: source

Pfizer Inc <PFE.N> is in talks to merge its off-patent drugs business with Mylan NV <MYL.O> in a stock deal, according to a source familiar with the matter.

Pfizer in talks to merge off-patent drugs business with Mylan

Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board

U.S. Senator Elizabeth Warren urged former U.S. Food and Drug Administration Commissioner Scott Gottlieb to immediately step down from Pfizer Inc's <PFE.N> board, three months after his departure from the health regulator.

Pfizer, Sanofi, to boost South African Biovac's vaccine output

South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

GSK-Pfizer joint venture gets conditional approval from South Africa's competition regulator

GlaxoSmithKline Plc <GSK.L> and Pfizer Inc's <PFE.N> planned joint venture received conditional approval from a South African regulator on Tuesday, clearing a hurdle in the creation of a consumer health giant with sales of 9.8 billion pounds.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up